Senores Pharmaceuticals Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Senores Pharmaceuticals Ltd filed with BSE on 03 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Senores Pharmaceuticals reported consolidated revenue of Rs 180 crore for Q1 FY27, up 36% year-over-year, with EBITDA of Rs 54 crore growing 87% and PAT of Rs 31 crore growing 56%. Regulated market revenue grew 42% while emerging market revenue grew 30%, and management said the ANDA portfolio nearly doubled to 58 approved ANDAs as of June 2026 from 30 a year earlier. Management reiterated full-year FY27 guidance of 30% to 40% revenue growth and 50% to 60% PAT growth, and outlined a three-to-four-year revenue target of Rs 2,500 crore to Rs 3,000 crore.
Numbers mentioned
Consolidated revenue: INR180 crores (Q1 FY27)
p. 5
“our quarterly revenue, our consolidated revenue from operations for Q1 FY27 stood at INR180 crores, reflecting the strong growth of 36% on Y-o-Y basis”
Deval Shah, page 5 of the filed PDF · View the filing
Regulated markets revenue growth: 42% Y-o-Y (Q1 FY27)
p. 6
“Revenue from regulated markets grew by 42% Y-o-Y and revenue from emerging markets grew by 30% Y-o-Y.”
Deval Shah, page 6 of the filed PDF · View the filing
India branded generics revenue: INR8 crores (Q1 FY27)
p. 6
“India branded generics stood at INR8 crores for the Q1 of FY27.”
Deval Shah, page 6 of the filed PDF · View the filing
Consolidated EBITDA: INR54 crores (Q1 FY27)
p. 6
“Consolidated EBITDA for Q1 of FY27 stood at INR54 crores, growing by a robust 87% on a Y-o-Y basis.”
Deval Shah, page 6 of the filed PDF · View the filing
EBITDA margin: almost 30%, up 810 bps Y-o-Y (Q1 FY27)
p. 6
“EBITDA margins stood at almost 30%, improving by 810 bps Y-o-Y.”
Deval Shah, page 6 of the filed PDF · View the filing
Profit after tax: INR31 crores (Q1 FY27)
p. 6
“Profit after tax for the quarter grew by 56% Y-o-Y and stood at INR31 crores.”
Deval Shah, page 6 of the filed PDF · View the filing
Approved ANDAs: 58 ANDAs (as of June 2026)
p. 4
“Over the past 12 months, we have nearly doubled our portfolio expanding from 30 ANDAs as of June 2025 to about 58 ANDAs approved ANDAs as of June 2026, out of which 23 ANDAs have been commercialized as we speak.”
Swapnil Shah, page 4 of the filed PDF · View the filing
Emerging market operating cash generated: INR18 crores (Q1 FY27)
p. 14
“In this quarter we have generated almost INR18 crores of operating cash.”
Deval Shah, page 14 of the filed PDF · View the filing
Apnar facility units produced: close to about 3 crores unit (Q1 FY27)
p. 11
“we produce in this quarter, we produced about 30 million units, close to about 3 crores unit at Apnar facility.”
Swapnil Shah, page 11 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue growth — approximately 30% to 40% · FY27
stated firmly by Swapnil Shah
p. 4
“Based on the current business outlook and execution visibility, we expect the revenue growth of approximately 30% to 40% and PAT growth for about 50% to 60% for FY27, with a similar growth trajectory expected to continue thereafter.”
Swapnil Shah, page 4 of the filed PDF · View the filing
PAT growth — about 50% to 60% · FY27
stated firmly by Swapnil Shah
p. 4
“Based on the current business outlook and execution visibility, we expect the revenue growth of approximately 30% to 40% and PAT growth for about 50% to 60% for FY27, with a similar growth trajectory expected to continue thereafter.”
Swapnil Shah, page 4 of the filed PDF · View the filing
Emerging market EBITDA margin — 18% to 20% · FY27 full year
stated conditionally by Swapnil Shah
p. 6
“we what we guided for about 18% to 20% EBITDA margin on emerging market, we are quite confident that we should be able to achieve that 18% to 20% EBITDA on the emerging market side.”
Swapnil Shah, page 6 of the filed PDF · View the filing
Revenue target — INR2,500 crores to INR3,000 crores · three to four years
stated as an aspiration by Swapnil Shah
p. 11
“we feel in about three to four years that's a solid roadmap for us to achieve INR2,500 crores to INR3,000 crores kind of a revenue with what we have currently in our pipeline.”
Swapnil Shah, page 11 of the filed PDF · View the filing
Capex — INR100-120 crores · FY27
stated firmly by Deval Shah
p. 13
“Capex what we have planned is '27 we have planned almost INR100-120 crores of capex across all the subsidiaries taken together.”
Deval Shah, page 13 of the filed PDF · View the filing
Capex run rate — INR60 crores to INR75 crores · next year
stated as an aspiration by Sanjay Majmudar
p. 13
“I think next year also you can take a minimum INR60 crores to INR75 crores run rate.”
Sanjay Majmudar, page 13 of the filed PDF · View the filing
Branded generics revenue — INR50 crores to INR60 crores · this year
stated conditionally by Swapnil Shah
p. 17
“From a branded generics, India domestic business is concerned, we expect to do about INR50 crores to INR60 crores this year, and there's also a significant growth that can come from the branded generics space in next two to three years time frame as well.”
Swapnil Shah, page 17 of the filed PDF · View the filing
European PIC/S approval for Chhatral facility — Q2, Q3
stated conditionally by Swapnil Shah
p. 5
“we are progressing towards obtaining European PIC/S approval for our Chhatral manufacturing facility by Q2, Q3.”
Swapnil Shah, page 5 of the filed PDF · View the filing
Zoraya and Amerisyn operationalization — September, October of this year
stated firmly by Swapnil Shah
p. 14
“Zoraya should get operationalized from September, October of this year and similar time frame is also for Amerisyn.”
Swapnil Shah, page 14 of the filed PDF · View the filing
Regulated market and emerging market revenue mix — 70/30 kind of mix · next few years
stated as an aspiration by Sanjay Majmudar
p. 17
“So having said that, just to add this 70/30 kind of mix between regulated and emerging markets should remain in this vicinity at least for next few years.”
Sanjay Majmudar, page 17 of the filed PDF · View the filing
Overall margin profile — 30-odd percent minimum
stated as an aspiration by Sanjay Majmudar
p. 18
“Yes, that's what we want to sustain as the minimum.”
Sanjay Majmudar, page 18 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management attributed the sequential dip to seasonality, noting H1 is typically weaker than H2, and reaffirmed full-year guidance of 18-20% margin.
Answered by Swapnil Shah
Asked by Hrushikesh Vrajesh Shah: Why did emerging market EBITDA margin decline sequentially from Q4 FY26 to Q1 FY27?
p. 6
“if you see a Q-o-Q comparison, maybe you'll see that's little dip, but going forward if you look at the whole full year picture, I think we what we guided for about 18% to 20% EBITDA margin on emerging market, we are quite confident that we should be able to achieve that 18% to 20% EBITDA on the emerging market side.”
Swapnil Shah, page 6 of the filed PDF · View the filing
Management said the focus shifted from sales growth to profitability this quarter after achieving a 5x sales jump the prior year.
Answered by Swapnil Shah
Asked by Hrushikesh Vrajesh Shah: Why did branded generics see a 2% de-growth this quarter?
p. 7
“So that has been you'll see the it's kind of little moderated, but from Y-o-Y basis, do we expect that growth of 30% to 40% on branded generics? We are confident of achieving those numbers.”
Swapnil Shah, page 7 of the filed PDF · View the filing
CFO clarified there was no restatement, only a change in presentation where foreign exchange fluctuations are now included within other income rather than shown separately.
Answered by Deval Shah
Asked by Hrushikesh Vrajesh Shah: Was there a restatement of other income figures for the June 2025 quarter?
p. 7
“there is no change in any policy or restatement or anything. It's just the presentation that has changed.”
Deval Shah, page 7 of the filed PDF · View the filing
Management said the increase reflects both acquisitions and continued in-house development consistent with their stated strategy.
Answered by Swapnil Shah
Asked by Sidharth Negandhi: What drove the sharp jump in ANDA pipeline numbers?
p. 7
“So, yes, on the ANDA, yes, there has there has been some acquisition that have happened and as we previously guided and discussed, wherever we see opportunity which fits in our sales and marketing strategy, we continue to either develop or acquire, right?”
Swapnil Shah, page 7 of the filed PDF · View the filing
Management attributed the sequential decline to a one-time foreign exchange gain of about Rs 14-15 crore in the prior quarter that did not recur.
Answered by Deval Shah
Asked by Sidharth Negandhi: Why did EBITDA and PAT decline sequentially in absolute terms?
p. 8
“It was almost INR14, INR15 crores of foreign exchange fluctuation, which this quarter is zero practically. So that is why we are seeing in absolute terms you are seeing some dip, mainly and solely it was due to foreign exchange fluctuation.”
Deval Shah, page 8 of the filed PDF · View the filing
Management said the sterile injectable plan was scaled down to a pilot project, with proceeds redirected to expand oral solid capacity, pending shareholder approval.
Answered by Swapnil Shah
Asked by Parth Sodha: What is the update on the sterile injectable project and unused IPO proceeds?
p. 10
“We strongly are going to look at sterile injectables and create similar differentiated portfolio and business model on that side as well, but that has been pushed to later half of this year from the execution standpoint.”
Swapnil Shah, page 10 of the filed PDF · View the filing
Management said they see a roadmap to Rs 2,500-3,000 crore revenue in three to four years with similar or slightly better profitability.
Answered by Swapnil Shah
Asked by Aanchal Maheshwari: What growth and margins are expected in regulated and emerging markets over the next one to two years?
p. 11
“we feel confident in terms of achieving those numbers with similar or slightly better profitability that's out there.”
Swapnil Shah, page 11 of the filed PDF · View the filing
Management said Apnar utilization is 80-90%, with FY27 capex of Rs 100-120 crore planned across subsidiaries.
Answered by Swapnil Shah
Asked by Umesh Laddha: What is the current utilization and capex plan for the Apnar facility and overall capex guidance?
p. 13
“from Apnar the utilization right now is close to about 80%-90%.”
Swapnil Shah, page 13 of the filed PDF · View the filing
Management quantified emerging market operating cash generation at Rs 18 crore and said it was too early to size the EU revenue opportunity.
Answered by Swapnil Shah
Asked by Divyam Ketan Doshi: How much cash did the emerging markets business generate, and how large could the EU opportunity become?
p. 14
“Revenue number we don't know yet and I think it is too premature to kind of have that mapped right now.”
Swapnil Shah, page 14 of the filed PDF · View the filing
Management said they would wait for clarity from the India-US trade agreement before assessing impact, noting they have manufacturing on both sides.
Answered by Swapnil Shah
Asked by Aniket Madhwani: How would potential US tariffs on generic medicines affect operations?
p. 15
“We already have a facility in the US. I mean so for us it's a neutral. We have facility on the both the side.”
Swapnil Shah, page 15 of the filed PDF · View the filing
Management declined to give a specific FY28 number, reiterating the longer-term three-to-four-year revenue target instead.
Answered by Sanjay Majmudar
Asked by Utkarsh Somaiya: Can FY28 PAT growth be expected to match the FY27 guidance of 50%?
p. 18
“I think, Mr. Utkarsh, the problem here is that we give you a specific guidance for this year and an overall guidance for next three four years. We want to grow, but putting an exact number for FY '28 is a bit premature.”
Sanjay Majmudar, page 18 of the filed PDF · View the filing
Risks flagged
Uncertainty and history of shifting tariff scenarios
p. 15
“And anyway they said two years, so it's too long a time for the way historically this tariff scenarios have kept on changing.”
Sanjay Majmudar, page 15 of the filed PDF · View the filing
Uncertain timing and outcome of NDA product approvals
p. 15
“because of it there are lot of moving parts, a lot of factors associated with it.”
Swapnil Shah, page 15 of the filed PDF · View the filing
General uncertain operating environment affecting business performance
p. 3
“enabled us to deliver a healthy performance despite an uncertain operating environment.”
Swapnil Shah, page 3 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.